Natural killer T (NKT) cells that express the semi‐invariant T‐cell receptor are innate‐like lymphocytes whose functions are controlled by self and foreign glycolipid ligands. Such ligands are presented by the antigen‐presenting, MHC class I‐like molecule CD1d, which belongs to a family of lipid antigen‐presenting molecules collectively called CD1. Activation of NKT cells
in vivo
results in rapid release of copious amounts of effector cytokines and chemokines with which they regulate innate and adaptive immune responses to pathogens, certain types of cancers and self‐antigens. The nature of CD1d‐restricted ligands, the manners in which they are recognised and the unique effector functions of NKT cells suggest an immunoregulatory role for this T‐cell subset. Their ability to respond fast and our ability to steer NKT cell cytokine responses to altered lipid ligands make them an important target for vaccine design and immunotherapies against autoimmune diseases. This article summarises our current understanding of CD1d‐restricted NKT cell biology and how these innate‐like lymphocytes control inflammation.
Key Concepts
CD1d molecules belong to a family of lipid antigen‐presenting molecules collectively called CD1.
CD1d molecules resemble peptide antigen‐presenting MHC class I molecules.
CD1d molecules restrict the specificity and functions of Natural killer T (NKT) cells.
NKT cells recognise self‐ and nonself‐lipid ligands.
Antigen recognition quickly activates NKT cells, which respond immediately by releasing proinflammatory and immunoregulatory cytokines and chemokines.
Activated NKT cells communicate with cells of the innate and adaptive immune systems by cell–cell interactions and/or via soluble mediators.
Such communications allow NKT cells to control immune responses to microbial pathogens and certain cancers.
NKT‐cell activation has beneficial and, sometimes, adverse effects on certain autoimmune and metabolic disorders.
NKT cells are targets for vaccine adjuvants and immunotherapies.